Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.

Jingyuan LiuChunjing DuLin PuPan XiangHaofeng XiongWen XieZhihai ChenAng Li

Published in: BMC infectious diseases (2021)

In patients with confirmed SARS-CoV-2 infection, no benefit was observed from interferon alfa-2b or LPV/r plus interferon alfa-2b treatment. The findings may provide references for treatment guidelines of patients with SARS-CoV-2 infection.

Keyphrases

replacement therapy
sars cov
dendritic cells
respiratory syndrome coronavirus
immune response
combination therapy